Navigation Links
NanoViricides Drugs Found To Be Highly Effective Against Most,Recent Strain of the H5N1 Avian Flu Virus

WEST HAVEN, Conn.--(BUSINESS WIRE)--May 7, 2007 - NanoViricides, Inc. (Pink Sheets: NNVC) presented results of recent animal studies against rabies and BSL3 in vitro studies against a Clade 2 H5N1 (avian influenza) virus at the 23rd Annual Symposium of the Pan American Society for Clinical Virology in Tampa, FL, on Wednesday, May 2. (Pan American Society for Clinical Virology (PASCV): Clinical Virology Symposium)

The BSL3 studies against Clade 2 H5N1, a Dec. 2006 isolate in Vietnam, showed that the nanoviricide developed against Highly Pathogenic Influenzas, FluCide-HP (TM), was highly effective in suppressing cytopathic effects (CPE), whereas the broad-spectrum nanoviricide against all influenzas, FluCide(TM), was slightly less effective than AviFluCide-HP. These findings were expected. Both of these candidates were significantly more effective than oseltamivir (Tamiflu(R)) in this blind study performed by the National Institute of Hygiene and Epidemiology (NIHE) scientists in Vietnam.

In addition, the antibody-fragment-based H5N1 specific (Clade 1, Vietnam, 2004-2005 strains) AviFluCide(TM) drug candidate was demonstrated conclusively by Vietnam scientists to significantly suppress CPE against this rgH5N1 strain (Clade 1), confirming previous results.

The Highly Pathogenic H5N1 subtype of influenza continues to rapidly evolve and is now found in two distinct subgroups, Clade 1 and Clade 2. According to CDC scientists, the Vietnam 2004/2005 strains belong to Clade 1, whereas the Indonesia 2006 (2007), Egypt 2006, and Vietnam 2006 (2007) strains are different and form the Clade 2 subgroup. The various Clade 2 strains are antigenically distinct from each other, but closer to each other than to Clade 1 strains.

"Highly Pathogenic Influenza strains of all clades possess the polybasic cleavage site. Thus FluCide-HP, designed against this site, is expected to be effective against all Highly Path ogenic influenza strains. It makes no difference to which type, subtype, or clade, they belong," said Anil R. Diwan, Ph.D., president of NanoViricides, Inc.

"We have shown that our drug candidates are the most effective drugs at present against even the newest subgroup of H5N1 viruses. Other companies continue to work on developing vaccines and drugs against the older Clade 1 H5N1 viruses, while we are working on the newest strains," said Eugene Seymour, MD, MPH, Chief Executive Officer of NanoViricides, Inc.

The Company plans to comment shortly on its in vitro/in vivo rabies studies.

About NanoViricides: http://www.nanoviricides.com

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. Nanoviricides is currently developing drugs against Common influenza, Bird Flu H5N1, Rabies, Dengue and other viruses with various collaborators. The Company recently signed a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research (http://wrair-www.army.mil/) for creating new treatments for dengue fever using NanoViricides' virus-killing nanomedicine technology. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.

Contact

NanoViricides, Inc.
Leo Ehrlich, 917-853-6440
leo@nanoviricides.com


'"/>




Related medicine technology :

1. Global Rabies Treatment May be Possible with NanoViricides Drugs
2. Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
5. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
6. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
7. Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment
8. Major Manufacturer of Unapproved and Adulterated Drugs
9. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
10. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
11. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Hutchison China MediTech (Chi-Med) ... the highly lucrative global oncology and immunology markets. ... first-in-class or best-in-class tyrosine kinase inhibitor (TKI) drugs, ... partners. HCM,s profitable Chinese healthcare business continues to ... progress of the mid-to-late-stage pipeline during 2016-17 (including ...
(Date:5/27/2016)... 27, 2016 Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that ... at two upcoming investor conferences: SeeThru Equity MicroCap ... New York City , NY When: ... Marcum MicroCap Conference   Where: Grand Hyatt Hotel, 109 ...
(Date:5/26/2016)... ALBANY, New York , May 26, 2016 ... Transparency Market Research "Medical Waste Management Market - U.S. Industry ... the medical waste management market in the U.S. was valued ... expand at a CAGR of 3.4% from 2015 to 2023 ... report provides exhaustive analysis of current and emerging needle free ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... In response to meager ... are unaware of the plight of aphasia. In collaboration with the American Aphasia ... campaign. , The link between stroke and aphasia is relatively unknown, but through ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... in scholarships to students studying complementary medicine. Allison Outerbridge is this year’s ... her award on May 18 at the university’s Student Leadership Awards ceremony. , ...
(Date:5/26/2016)... ... 26, 2016 , ... W.S. Badger Co. Inc ., the maker of ... When Work Works Award for its use of effective workplace strategies to increase business ... project administered by the Families and Work Institute (FWI) and the Society for Human ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Connor ... women’s basketball as a partner for the Tamika Catchings Legacy Tour that ... the industry leader in hardwood basketball surfaces in all forms and levels of the ...
(Date:5/26/2016)... ... 26, 2016 , ... There are nearly 14.5 million people living with and ... On Sunday, June 5, 2016, communities around the world will gather to recognize these ... National Cancer Survivors Day® is an annual worldwide Celebration of Life that is held ...
Breaking Medicine News(10 mins):